Status of work in August
AOTMiT begins work on the Ministry of Health’s orders in August:
- Tevimbra (tislelizumab) in the treatment of patients with cancer of the esophagus, gastroesophageal junction, and stomach
- Tevimbra (tislelizumab) in the treatment of patients with cancer of the esophagus, gastroesophageal junction, and stomach
- Tevimbra (tislelizumab) in the treatment of patients with esophageal cancer, gastroesophageal junction cancer, and gastric cancer First line in combination with ChT with expression of
- Imfinzi (durvalumab) for consolidation treatment of DRP
The listed order is available on the AOTMiT Public Information Bulletin.